Investor Relations: TSXV:NRX | OTCQB:NRXBF | FSE: J90
ExoPTEN is NurExone’s lead therapeutic candidate, combining exosomes with PTEN-inhibiting siRNA. In preclinical traumatic spinal cord injury studies, brief treatment was associated with neural regeneration and improved functional outcomes, including recovery of motor, sensory and bladder function.
ExoPTEN is being advanced first for acute spinal cord injury, with optic nerve injury as an additional preclinical indication. Its potential application in facial nerve injury is being explored through an early-stage academic research collaboration.
NurExone produces MSC-derived exosomes using proprietary production processes designed to support quality, consistency, and scalability.
Defined therapeutic cargo, including siRNA and other molecular payloads, can be selected based on the biological target and therapeutic indication.
NurExone’s proprietary loading technology is used to load defined therapeutic cargo onto exosomes, creating exosome-based nanodrugs designed for targeted regenerative applications.
With ExoPTEN as its lead therapeutic candidate, NurExone is building a broader exosome-based modality platform designed to support multiple indications, scalable production, and future commercial opportunities, from therapeutic development to selected aesthetics and wellness applications.
